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ABSTRACT  
Prognostic factors predictive of outcome in childhood Acute Lymphoblastic Leukaemia 
(ALL) are used to risk assign treatment groups.  
 
This study aimed to identify the relevance of these prognostic features in the modern 
treatment era in South African children. A retrospective analysis of the presentation 
clinical and laboratory features and treatment outcomes of all children treated for 
Precursor B cell ALL at the Johannesburg Hospital was performed.  
 
Between January 1997 and May 2007, 100 children were reviewed. Clinical features 
(age, race and gender) emerged as significant prognostic variables. Laboratory features 
(white cell count and genetic features) lacked significance. Early morphologic response 
on day 15 identified a subgroup associated with a favourable outcome. However the 
presence of > 5% blasts was not significantly predictive of relapse or death at this time 
point. Minimal residual disease (MRD) detection by modified immunoglobulin gene 
rearrangement and flow cytometry techniques did not improve the predictive value of the 
morphological assessment.  
 
In a low resource setting, the challenge is to design cost effective MRD detection 
methods to improve the identification of patients at risk for relapse.  
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1. INTRODUCTION 
This is a retrospective record review of the presenting features and clinical outcomes of 
therapy of children with Precursor B cell Acute Lymphoblastic Leukaemia (ALL). This 
was conducted at the Johannesburg Hospital Paediatric Oncology Unit over a 125 month 
period. This is the main referral centre for children with haematological malignancies in 
Johannesburg.  
 
1.1 Definition 
ALL is a clonal proliferation of lymphoblasts, involving the bone marrow (BM) and 
peripheral blood (PB). ALL is the most common childhood cancer accounting for 30% of 
childhood malignancies (Pui, et al 1995). ALL is sub-typed according to the cell lineage 
into Precursor B cell ALL and Precursor T cell ALL (Harris, et al 1997). Precursor B cell 
ALL is the most common childhood subtype, which accounts for approximately 84% of 
cases (Camitta BM 1997). It is further divided into three groups according to the stage of 
B cell maturation on immunophenotypic analysis.1 
 
 
                                               
 
1 Precursor B cell ALL subtypes include pro-B ALL which express early B lineage 
markers (CD19, CD22, and CD79a but no CD10 and no cytoplasmic or surface 
immunoglobulin{Ig}), common ALL which in addition to CD19, CD22, and CD79a, also 
express CD10 and pre-B ALL which express CD10 and cytoplasmic Ig.  
B cell ALL is treated differently from Precursor B and T cell ALL with a lymphoma 
based approach and is no longer included in the World Health Organization classification 
of ALL (Harris, et al 1997). 
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1.2 Background 
Remarkable progress has been achieved in the management of children with ALL such 
that children diagnosed with Precursor B cell ALL achieve a five year event free survival 
(EFS) of greater than 80% in large clinical trials (Pui and Evans 1998, Silverman, et al 
2001).  
 
As a result of improved outcome with treatment intensification, clinical research has 
focused on identifying clinical and laboratory prognostic features at diagnosis for risk 
stratification (Kersey 1997). In this way, only high risk cases are treated intensively with 
less toxic therapy reserved for low risk cases (Friedmann and Weinstein 2000).  
 
More than 50 markers that correlate significantly with prognosis have been identified 
(Donadieu and Hill 2001). These prognostic features have been incorporated in various 
combinations into classification systems in order to assign treatment groups into high and 
standard risk groups (Tables 1.1 and 1.2).  
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Table 1.1.  
Clinical and laboratory prognostic factors in childhood Acute Lymphoblastic Leukaemia 
(Pui, et al 1990, Smith, et al 1996) 
RISK FACTORS FAVOURABLE OUTCOME UNFAVOURABLE OUTCOME 
Age 1-10 years < 1 and > 10 years 
Gender Female Male 
Race Asian, white Black 
WCC at diagnosis < 50 x 10 9/l > 50 x 10 9/l 
DNA index > 1.16  < 1.16  
Chromosome number/leukaemic 
cell 
> 50 < 45 
Cytogenetics Trisomies 4,10 and 17 t(4;11) in infants and t(9;22) 
Molecular genetics TEL-AML1 MLL in infants and BCR-ABL 
Day 8 prednisone response < 1 x 10 9/l > 1 x 10 9/l 
Immunophenotype 
 
Precursor B cell 
 
Precursor T cell, B cell 
CNS status CNS 1(no blasts) CNS 2 (< 5 blasts/ml)-3(≥ 5 blasts/ml) 
Key: 
WCC, white cell count;   
CNS, central nervous system 
 
 
 
 
 
 
 
 
 
 
 
 4
Table 1.2.  
Current risk classification systems  
Group/ Institution Features 
SJCRM 
Low risk 
 
 
 
 
High risk 
 
 
Age 1-9, WCC < 50 x 109/l, DNA index 1.16-1.6 or TEL-
AML1 fusion, MRD < 0.01% at end of induction, no BCR-
ABL fusion or MLL rearrangement or t(1;19), no CNS or 
testicular disease 
 
BCR-ABL fusion, induction failure, MRD > 1% at end of 
induction 
BFM 
Standard risk 
 
 
Medium risk 
 
 
High risk 
 
 
Prednisone good response, molecular remission on day 
33, no BCR-ABL fusion or MLL rearrangement 
 
Prednisone good response, morphologic remission on day 
33, no BCR-ABL fusion or MLL rearrangement 
 
Prednisone poor response, no morphologic remission on 
day 33, presence of BCR-ABL fusion or MLL 
rearrangement, ≥ 0.1% leukaemic cells at end of induction 
DFCI 
Standard risk 
 
 
High risk 
 
Age 1-9, WCC<50 x 109/l, no BCR-ABL fusion, no T cell 
immunophenotype, no mediastinal mass, remission day 31 
 
WCC>50 x 109/l, age <1 or >10, CNS 2 or 3, presence of 
BCR-ABL fusion, T cell, mediastinal mass 
COG 
Low 
 
 
 
 
Standard 
 
 
 
High 
Very high 
 
Age 1-9, WCC < 50 x 109/l, trisomies 4,10 and 17 or TEL-
AML1 fusion, rapid early response, no CNS or testicular 
disease, no BCR-ABL fusion, E2A-PBX1 fusion or MLL 
rearrangement 
 
Age 1-9, WCC < 50 x 109/l, no trisomies 4,10 and 17, no 
TEL-AML1 fusion, or one of these genetic features but slow 
early response 
 
No very high risk features 
BCR-ABL fusion, hypoploidy, DNA index < 0.81, induction 
failure 
Key: 
SJCRM, St Judes Children’s Research Hospital;                                                  DFCI, Dana-Farber cancer Institute;  
BFM, Berlin-Frankfurt-Munster;                                                                             COG, Children’s oncology group 
CNS, central nervous system;                                                                               MRD, minimal residual disease 
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Most study groups use age and white cell count (WCC) at diagnosis for stratification 
because these features have consistently been shown to be important independent 
prognostic indictors (Ribeiro and Pui 1993). More recently treatment protocols classify 
patients on the basis of the genetic features of the leukaemic blasts and an early response 
to remission-induction treatment (Pui, et al 2004c). These features have been shown to 
predict more accurately the outcome rather than presenting clinical (age, gender, race) 
and laboratory features (WCC, DNA index, immunophenotype) which have lost 
prognostic significance with improvements in therapy (Pui, et al 2004a). 
 
1.2.1 Acute Lymphoblastic Leukaemia in South African children 
Presenting features predictive of outcome have also been described in South African 
children (Table 1.3). 
 
Table 1.3.   
Risk factors evaluated for influence on event free survival in South African children with 
Acute Lymphoblastic Leukaemia 
Study No. of patients Centre Risk factors 5 year EFS  p value 
Wessels, et al 
1997 
(1983-1995) 
96 Tygerburg Hospital Age < 2 and  
> 8 years 
 
WCC>20 x 10 9/l 
25% and 20% 
 
 
21% 
0.002 
 
 
0.02 
Macdougall  1985 
(1974-1982) 
130 Johannesburg & 
Chris Hani 
Baragwanath 
Hospitals 
Age < 2 and  
> 10 years 
 
Race-black 
 
CNS disease 
- 
 
 
32% 
 
- 
0.0006 
 
 
0.0001 
 
0.006 
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At Johannesburg Hospital, the Paediatric Oncology Unit have adopted treatment 
protocols from large co-operative trials namely, the Toronto C (1997-2001) and modified 
ALL Berlin-Frankfurt-Munster (BFM) 95 (2002 to date) protocols. As a result of the poor 
survival rates previously reported in South African children with ALL treated according 
to standard risk protocols (MacDougall 1985), children in this study were not assigned to 
standard risk treatment. According to the modified BFM 95 protocol, patients were 
classified into medium and high risk groups on the basis of the genetic features of the 
leukaemic blasts and an early response to remission-induction treatment (Table 1.2) 
(Schrappe, et al 2000a).  
 
1.2.2 Genetic features 
The differences in treatment outcome for distinct age groups and to a lesser extent WCC 
groups can be attributed to the specific genetic abnormalities that the leukaemic cells 
harbour (Pui, et al 2004a). This is demonstrated by the poor prognosis of infant ALL, 
which results from the high frequency of MLL-AF4 rearrangement involving 
chromosome band 11q23 in this age group (Pui, et al 2002). Seventy five percent of 
childhood ALL cases have specific genetic abnormalities with therapeutic and prognostic 
significance at presentation (Pui, et al 1990). The best characterised chromosomal 
translocation is t (9; 22)/ BCR-ABL rearrangement designated as the Ph chromosome, 
which is present in three to five percent of childhood ALL cases. This has remained a 
poor prognostic feature despite treatment intensification (Crist, et al 1990).  
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Favourable genetic features associated with Precursor B cell ALL include hyperdiploidy 
(> 50 chromosomes or a DNA index > 1.16) and the t(12;21)/ TEL-AML1 rearrangement 
(Romana, et al 1995, Trueworthy, et al 1992). However in recent trials, the prognostic 
influence of hyperdiploidy has been found to closely correlate with other favourable 
genetic features such as trisomies of chromosome four and ten (Harris, et al 1992). The 
presence of the TEL-AML1 rearrangement has also lost prognostic impact in recent 
studies (Harbott, et al 1997, Satake, et al 1997, Seeger, et al 1998). 
  
1.2.3 Early response to remission-induction treatment 
Because clinical outcome is determined by many factors including the genetic features of 
the leukaemic cells, measurement of an early response to therapy has consistently shown 
independent prognostic significance.  An early response to therapy is defined as evidence 
of an initial response to therapy prior to the BM evaluation at the end of induction 
therapy (Gaynon, et al 1997). This is a significant time point in treatment because 
augmentation of therapy for a slow early response improves survival (Nachman, et al 
1998). The persistence of blasts in the PB or BM after the first week or two weeks of 
induction treatment has been found to be highly predictive of disease recurrence. 2 
 
                                               
 
2 Early response has been measured by morphologic evaluation of blasts in the PB after 
one week of prednisone therapy in BFM protocols since 1986 (Schrappe, et al 1996). 
Investigators from SJCRM have shown that the presence of > 1 x 10 9/l PB blasts after 
one week of conventional induction chemotherapy is also associated with a poor 
prognosis (Gajjar, et al 1995). Other authors have found BM blasts of ≥ 5% during 
induction therapy predict relapse (Sandlund, et al 2002, Steinherz, et al 1996). 
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1.2.4 Minimal residual disease 
Measurement of an early response to therapy lacks predictive value, as most relapses 
occur in patients with standard risk features. More recently, the detection of minimal 
residual disease (MRD) has been demonstrated to provide a more sensitive assessment of 
treatment response (Cave, et al 1998, Coustan-Smith, et al 2000, Campana and Coustan-
Smith 2004, Dworzak, et al 2002,). This is a measure of the lowest level of detectable 
disease during morphologic remission. Estimates by conventional morphology have 
limited sensitivity, as even in morphologic remission patients may still have as many as 
1010 leukaemic cells in the BM (Campana 2003, Szczepanski, et al 2001).  
 
Currently several treatment groups (refer to Table 1.2) utilise monitoring of MRD at the 
end of remission induction therapy and/or sequential time points during treatment in 
order to identify patients at increased risk for relapse (Pui, et al 2004b). The detection of 
MRD is most frequently performed by Polymerase Chain Reaction (PCR) analysis or 
multi-parameter flow cytometry (FC). MRD detection by PCR targets clonal Ig gene 
rearrangements and fusion genes (Beishuizen, et al 1994). While only 30-40% of ALL 
patients have specific chromosomal aberrations with well-defined breakpoint fusion 
regions, virtually all Precursor B cell ALL patients (> 95%) have rearranged 
immunoglobulin heavy (IgH) genes (Campana and Pui 1995). The selection of the 
methods used for assessment of MRD depends on the expertise and facilities present in 
each centre. 
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1.2.4.1 PCR 
Studies of clonal gene rearrangements have demonstrated a significantly increased risk of 
relapse in cases with evidence of MRD (Cave, et al 1998) (Foroni, et al 1999) (van 
Dongen, et al 1998). This is, however, a laborious procedure which requires analysis of 
multiple genetic targets (to reduce the risk of clonal evolution of the leukaemic clone 
during the disease course). PCR techniques are currently performed by two methods: 
these use either patient specific or consensus primers. Most academic centres favour the 
use of the former more sensitive (one leukaemic cell per 10 5 -10 6 cells) and specific 
method. This detects the DNA sequence of the IgH gene rearrangement of the leukaemic 
clone by sequencing the rearrangements and synthesizing allele specific primers (Cave, et 
al 1998, van Dongen, et al 1998). This is however costly and time consuming and limits 
application as a routine diagnostic tool. The latter method is simpler and more widely 
applicable, however it offers a lower level of detection of MRD (one leukaemic cell per 
10 3 -10 4 cells) (Brisco, et al 2001, Nizet, et al 1993, Sykes, et al 1997). This PCR 
technique uses consensus primers to amplify junctional sequences for each patient. 
 
1.2.4.2 Flow Cytometry  
FC analysis is used to type leukaemic cells by defining their cell surface antigen (Ag) 
expression. Aberrant Ag expression on ALL blasts can be used to distinguish leukaemic 
cells from normal lymphoid cells. The use of broad antibody panels is a rapid technique 
and enables MRD monitoring in more than 90% of patients with a sensitivity of 0.01% 
(one leukaemic cell per 10 4 cells) (Kerst, et al 2005). 
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1.2.4.3 Detection of Minimal Residual Disease at Johannesburg Hospital  
The presence of MRD at the end of remission induction therapy (day 33) has recently 
been included in the high risk BFM classification. At the National Health Laboratory 
Service (NHLS) in Johannesburg, the assessment of MRD is performed by the 
complementary use of PCR with consensus primers and FC with limited antibody panels. 
These are performed at sequential time points during therapy. This combination of 
simplified MRD detection methods was initiated in 1996 on the basis of available 
technology and cost considerations. In a low resource setting such as South Africa, the 
monitoring tests employed to detect MRD, have been modified in order to make this 
testing readily available to all patients. The detection of MRD is currently not used to 
guide therapy in our unit as the clinical significance of MRD and its predictive value in 
relation to other prognostic features of ALL has never been formally assessed.  
 
1.3 Research questions 
1. Are the clinical and laboratory risk factors (refer to Table 1.1 and 1.3) previously 
shown to be prognostic in large multi-centre and South African studies of children 
with Precursor B cell ALL currently predictive of outcome with intensification of 
therapy in the modern treatment era?  
 
2. Are genetic features and an early treatment response, used to risk assign treatment 
groups, predictive of outcome in this cohort?  
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3. Does the detection of MRD by modified techniques at sequential time points 
during therapy offer an improved sensitivity and specificity when compared to 
morphologic analysis? 
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2. PATIENTS AND METHODS 
2.1 Patients 
This study includes all children with the diagnosis of Precursor B cell ALL who were 
treated at the Johannesburg Hospital Paediatric Oncology Unit between January 1997 and 
May 2007. The diagnosis of Precursor B cell ALL was established according to standard 
morphological (French American British), cytochemical and immunophenotypic criteria 
(Catovsky and Matutes 1992). Children who were diagnosed and transferred to other 
centres for management were excluded from this analysis.  
 
Clinical and laboratory data at disease presentation was collected from patient clinic files 
or the NHLS computer database.  
 
Clinical data included age, gender and race. Laboratory data recorded included white cell 
count (WCC), FISH analysis for a t(9;22)/BCR-ABL rearrangement; a t(12;21)/TEL-
AML1 rearrangement and a t(4,11)/MLL-AF4 rearrangement, the DNA Index/Ploidy as 
determined by FC and the karyotype on cytogenetic analysis.  The presence of central 
nervous system (CNS) disease was not included as this was not detected in any of the 
patients studied.  
 
The WCC at diagnosis was categorized as < 50 x 10 9/l and > 50 x 10 9/l and age as < 2 
years, 2-10 years and > 10 years. The age groups applied differed from the National 
Cancer Institute criteria which has defined a uniform age range of 1- 9.9 (Smith, et al 
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1996). This was because an age range of 2-10 years was previously applied in South 
African cohorts and was significantly associated with survival.  
 
This study was approved by the University of the Witwatersrand’s Human Research 
Ethics committee (protocol number MO60632).  
 
2.2 Treatment protocol 
All children diagnosed with ALL from January 1997 to December 2001 were treated 
uniformly according to the Hospital for Sick Children’s (SickKids, Toronto, Canada) 
high risk ALL protocol (Toronto C protocol). This is a chemotherapy regimen adapted 
from the approach of the BFM study group (Schrappe, et al 2000b).  
 
In December 2001, a modified BFM 95 protocol was introduced in order to standardise 
treatment approaches between the Paediatric Oncology institutions in Gauteng. All 
children were primarily assigned to a medium risk group. Patients with one of the 
following features were changed to a high risk protocol: a t(9;22) rearrangement, or a 
t(4;11) rearrangement or failure to achieve an early response to remission-induction 
treatment. This was determined by the PB response to prednisone on day eight (a poor 
response defined as blasts of  > 1 x 10 9/l) or failure to achieve morphologic remission on 
day 33 of induction treatment (defined as  ≥ 5% leukaemic blast cells on BM aspirate). 
 
Treatment schedules for patients treated according to the Toronto C and modified ALL 
BFM 95 protocol are detailed in Appendix A and B. Briefly, the Toronto C protocol 
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consisted of induction therapy with prednisone, vincristine, daunorubicin and 
L’asparaginase; CNS prophylaxis with intrathecal methotrexate (all patients with CNS 
disease received triple intrathecal chemotherapy with methotrexate, hydrocortisone and 
Ara-C); consolidation therapy with cyclophosphamide, Ara C and 6-mercaptopurine and 
intrathecal chemotherapy; re-induction pulses with dexamethasone, vincristine, 
adriamycin and L’asparaginase, followed by cyclophosphamide, Ara C and 6-thioguanine 
and intrathecal chemotherapy; and maintenance therapy with: vincristine, prednisone, 
methotrexate and intrathecal chemotherapy. Trimethoprim-sulfamethoxole was given to 
all patients daily for three consecutive days per week post remission induction as 
prophylaxis against Pneumocystis jiroveci pneumonia. Chemotherapy was continued for 
36 months. 
 
The medium risk modified ALL BFM 95 protocol differed from the above regimen in 
that prednisone monotherapy was administered during induction for seven days; followed 
by vincristine and daunorubicin weekly. Intrathecal hydrocortisone was administered as 
part of CNS prophylaxis. The high risk blocks consisted of six cycles of multi-agent 
chemotherapy on a monthly basis, commencing one week after induction therapy. 
 
2.3 Treatment response  
Treatment response was measured by BM examinations performed at times specified by 
the relevant Toronto C and modified ALL BFM 95 protocols. Namely, an early response 
to remission induction therapy was measured at day 14 and 15 of treatment respectively 
(combined and referred to as day 15); remission was determined on day 28 and 33 of 
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induction therapy respectively (combined and referred to as day 33); and follow-up was 
performed prior to commencing maintenance therapy, at completion of treatment and if 
clinically indicated. Evaluation of blasts in the PB after one week of prednisone therapy 
was included as a measure of an early response from 2001 with adoption of a modified 
ALL BFM 95 protocol.  
 
With each BM examination, MRD was determined by complementary use of PCR and 
FC. Follow-up with PCR analysis was not possible in patients who were polyclonal at 
diagnosis or in whom no baseline PCR was performed. In addition, as PCR was not used 
to guide management in these patients, owing to socio-economic constraints PCR was not 
performed at all time points in every patient. 
 
2.4 Morphologic analysis 
The diagnosis of Precursor B cell ALL was based on light microscopic appearance of BM 
smears. Morphologic remission was defined as < 5% leukaemic blasts on a regenerated 
marrow specimen at the end of remission induction therapy.  
 
The number of leukaemic blasts in the PB on day eight was calculated from the absolute 
WCC and percentage of blasts. This was determined by morphologic and 
immunophenotypic analysis of the PB. The presence of < 1 x 10 9/l was defined as an 
early prednisone response. 
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2.5 Cytogenetic and FISH analysis 
Diagnostic karyotyping of leukaemic cells was performed by the department of 
cytogenetics, NHLS. Banded chromosomes were prepared from 24 hour cultured 
preparations of fresh bone marrow.  
FISH Analysis of t(12;21) and t(9;22) was initiated in 2000 and 2001 respectively. The 
LSI BCR-ABL and TEL-AML1 extra signal dual colour DNA probes (VYSIS) were used 
to detect the presence of t(9;22) and t(12;21) respectively. 
 
2.6 Ploidy analysis 
DNA content of the leukaemic blasts was determined by FC. The DNA index was 
defined as the ratio of DNA content of the leukemic G0/G1 cells versus normal diploid 
cells. Hyperdiploidy (which correlates with > 50 chromosomes) was defined according to 
the presence of two peaks and a DNA index > 1.16. 
 
2.7 Minimal residual disease analysis 
2.7.1 IgH PCR 
Genomic DNA was extracted from bone marrow aspirates or EDTA collected PB using 
High Pure PCR template Preparation Kit (Roche, Mannheim, Germany) as indicated by 
the manufacturer. For the detection of gene rearrangements within framework region two 
(FR2) and framework region three (FR3), a nested PCR procedure was performed. The 
forward primer used for both the first round and nested PCR for the FR2 reaction was: 
5’TGG (G/A) TC CG(C/A) CAG (G/C) C(T/C)(T/C) CN GG 3’and for the FR3 reaction: 
5’ ACA CGGC (C/T) (G/C) TGT ATT ACT GT 3’.  The reverse primers used in both the 
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FR2 and FR3 first round PCR were: 5’ TGA GGA GAC GGT GAC 3’, and the second 
round: 5’ GTG ACC AGG GTN CCT TGG CCC CAG 3’.  A final concentration of 10 
pmoles/ml of primer was added to each reaction. The annealing temperature was 50°C for 
the first round and 53°C for the second round.  
 
PCR products were separated in a 2% agarose gel and visualised with Ethidium bromide 
staining on a UV transiluminator. Accepted size ranges for FR2 and FR3 products ranged 
from 120 to 300 base pairs and 80 to 120 base pairs respectively. 
 
All samples were amplified with primers specific for the b-globin housekeeping gene to 
ensure that sufficient and high quality DNA was extracted during the extraction 
procedure. The primer set used for this amplification included the GF: 5’ AGT GCT 
GCA AGA AGA ACA ACT ACC 3’; and the GR: 5’ CTC TGC ATC ATG GGC AGT 
GAG CTC 3’. An annealing temperature of 63°C was used to perform a 40-cycle 
programme. These primers yielded a 330bp sized product to confirm DNA integrity. 
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Key: 
Lane 1: blank 
Lane 2: polyclonal control 
Lane 3: monoclonal control 
Lane M: molecular weight ladder 
 
Figure 2.1.  
PCR products in a 2% agarose gel 
 
 
2.7.2 Flow cytometry 
Pre-treatment heparinised bone marrow aspirate samples were submitted for surface 
marker analysis. Ficol-separated mononuclear cells were stained with monoclonal 
antibodies conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), 
allophycocyanin (APC) and peridinin chlorophyll protein (PerCP). The combination of 
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CD10, CD19, HLA DR and no surface membrane Ig expression was used to define 
Precursor B cell ALL.  
 
Analysis was performed on a dual-laser FACSCalibur (Becton Dickinson, San Jose, CA, 
USA) equipped with Cell Quest Pro and PAINT-A-GATE Pro software on a maximum 
of 10 000 events per sample. 
A limited analysis was performed at each follow-up time point during treatment. The 
monoclonal antibody combinations included: CD19/CD10/CD45 and/or 
HLADR/CD33/CD34 as well as relevant isotypic controls. These combinations were not 
standardised and varied according to the presentation phenotype. The combinations used 
rely on differences in brightness of the expression between leukemic cells and normal 
lymphoid progenitors. CD19/CD10 co-expressing cells which were large in size and/or 
cells that accounted for > 5% in number were used to define the presence of MRD. 
 
2.8 Statistical analysis 
EFS is defined as survival from the date of diagnosis until the date of relapse, death or 
last follow-up. EFS rates were estimated by the Kaplan-Meier survival function. The log-
rank test was used to test the equality of survival curves. The significance of differences 
in means was tested using t- and F- tests. A p-value of < 0.05 is considered statistically 
significant. A Cox regression was used to determine hazard rates. All analyses were 
conducted using Stata 9.2 software. 
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3. RESULTS 
3.1 Patient characteristics 
There were 110 patients diagnosed with Precursor B cell ALL during the study period. 
There were ten non-disease related deaths from causes including sepsis, haemorrhage, 
and chemotherapy-related mortality, which were censored at the time of event on EFS 
analysis.  
 
An average of 11 new cases of ALL were diagnosed and treated annually at 
Johannesburg Hospital Paediatric Oncology Unit (Figure 3.1).The average length of 
follow-up for the entire cohort was 55.8 months (range 0.4 – 122.5). The follow-up was 
79.6 months for patients treated according to the Toronto C protocol and 27.8 months for 
those treated according to a modified ALL BFM 95 protocol. 
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Figure 3.1.  
Paediatric cases diagnosed with Precursor B cell Acute Lymphoblastic Leukaemia 
between 1997 and 2006. 
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3.1.1 Clinical 
The presenting clinical features and treatment outcome of the 100 patients analysed are 
summarised in Table 3.1 and 3.2.  
 
Table 3.1.  
Study population clinical characteristics (n=100) 
 
 
Fe at ur es  
 
 
N u mb er  o f  P at i e n t s   
A ge   
<  2  an d  >  1 0  ye ars  
2 - 10  ye ars  
9  an d  1 5  
76  
G en d er   
M a l e  
F em al e  
57  
43  
R a ce   
B l ac k  
W hi t e  
As i an  
M i x ed  
36  
46  
11  
7  
 
 
Table 3.2:  
Treatment outcome according to clinical features 
 
 
Fe at ur es  
 
 
5  y ear  E FS  ( %)  (9 5 % C I )  
 
p  v a lu e  
A ge    
<  2  an d  >  1 0  ye ars  
2 - 10  ye ars  
64 . 8  [ 4 1 . 4  -  80 . 7 ]  
86 . 4  [ 7 5 . 2  -  92 . 7 ]  
 
0 . 0 18  
G en d er    
M a l e  
F em al e  
68 . 7  [ 5 4 . 0  -  79 . 5 ]  
97 . 6  [ 8 3 . 4  -  98 . 9 ]  
0 . 0 01  
R a ce    
B l ac k  
N on- b l ac k  
68 . 9  [ 4 9 . 7  -  82 . 1 ]  
87 . 5  [ 7 5 . 4  –  9 3 . 9 ]  
0 . 0 06  
K ey:  
C I ,  c on f id en c e  i n t er v a l  
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3.1.1.1 Age 
As expected the incidence of childhood ALL was highest in the age-group of 2-10 years. 
Ages of the children in this study ranged from 3 months to 14.6 years. Children aged < 2 
years and > 10 years were associated with an increased risk of relapse (Table 3.2).  
 
3.1.1.2 Gender 
There were a higher proportion of boys, which is consistent with findings in other large 
cohorts of children with ALL (Chessells, et al 1995). Male gender was predictive of an 
unfavourable outcome (Table 3.2).  
 
3.1.1.3 Race 
In contrast to other published series, black children represented a larger proportion of this 
study population (36%) as opposed to the 6.5% reported by Pui, et al 2003 and 7% by 
Bhatia, et al 2002. Black race was predictive of an unfavourable outcome (Table 3.2). 
Black children were more likely than non black children to have poor clinical and 
laboratory prognostic features. Black children were more likely to be male than non black 
children (74% versus 47%). Black children had a higher frequency of being diagnosed at 
age > 10 years than non black children (26% black versus 8%) and a slightly higher 
frequency of t(9;22) (7% of black children versus 4%). These poor risk features did not 
achieve statistical significance on Cox regression analysis.  
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3.1.2 Laboratory  
The presenting laboratory features and treatment outcome are summarised in Table 3.3 
and 3.4. 
 
Table 3.3.  
Study population laboratory features (n=100) 
 
Fe at ur es  
 
 
N u mb er  o f  p at i e n t s   
P lo idy   
H yp erd i p l o i d  
D i p l o i d  
24  
70  
t (9 ; 2 2)   
BC R - A B L  
 
Abs en t  
P r es en t  
47  
6     
t (1 2; 2 1)   
T EL- AM L1  
 
Abs en t  
P r es en t  
53  
17  
t (4 ; 1 1)   
M LL-A F 4  
 
Abs en t  
P r es en t  
55   
0  
W C C  (x  10  9 / l )   
>  50  
<  50  
12   
88  
 
 
 2 4
Table 3.4: 
Treatment outcome according to laboratory features 
 
Fe at ur es  
 
 
5  y ear  E FS  ( %) ( 9 5 % C I )  
 
p  v a lu e  
P lo idy    
H yp erd i p l o i d  
D i p l o i d  
90 . 8  [ 6 8 . 1 - 9 7 . 6 ]  
76 . 38  [ 63 . 08 -8 5 . 4 2 ]  
0 . 3 4  
t (9 ; 2 2)   
BC R - A B L  
  
Abs en t  
P r es en t  
69 . 8  [ 4 7 . 7 - 8 3 . 9 ]  
41 . 7  [ 5 .6 - 7 6 . 7 ]  
0 . 1  
t (1 2; 2 1)   
T EL- AM L1  
  
Abs en t  
P r es en t  
65 . 89  [ 48 . 7 - 78 .5 ]  
88 . 2  [ 6 0 . 6 - 9 6 . 9 ]  
0 . 1 8  
t (4 ; 1 1)   
M LL-A F 4  
  
Abs en t  
P r es en t  
-  -  
W C C  (x  10  9 / l )    
>  50  
<  50  
80 . 2  [ 4 0 . 3 - 9 4 . 8  
82 . 1  [ 7 1 . 4 - 8 9 . 0 ]  
0 . 8 5  
 
 
 
3.1.2.1 WCC 
The average WCC at diagnosis was 24.7 x 10 9/l (range 0.8-241.6). WCC was not 
significantly predictive of outcome.  
 
3.1.2.2 Genetic features 
In the case of the presence of a t(9;22) or t(12;21) on FISH analysis there were 
insufficient numbers tested. There were no cases of the MLL-AF4 rearrangement 
detected in the 55 patients tested. 
 
The most common fusion gene identified was the TEL-AML1 rearrangement. The 
presence of a TEL-AML1 rearrangement, although not statistically significant, was 
associated with an improved survival. In this study the TEL-AML1 rearrangement was 
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associated with a WCC of less than 50 x 10 9/l and an older average age of 6.7 years 
(range 2.2-13.9).This contrasts to the peak incidence between the ages of one and five 
years described in other cohorts.  
 
The incidence of the BCR-ABL rearrangement was higher than the three to five percent 
reported in other large childhood studies (11.3%). The presence of a BCR-ABL 
rearrangement, although not statistically significant, was associated with a poor 
prognosis.  Children with a Ph chromosome had an average WCC of 84.0 x 10 9/l at 
diagnosis (range 3.8-241.6) and presented at an older average age of 8.3 years (range 3.4-
13.6). Five of these patients were treated according to high risk protocols (there was one 
induction failure). There were two relapses at 27.3 and 13.4 months respectively after 
achieving morphologic remission. The former patient transformed to an Acute Myeloid 
Leukaemia. 
 
Ploidy analysis was performed in 94 patients at diagnosis (Table 3.5). Hyperdiploidy was 
associated with a favourable prognosis, although this did not reach statistical 
significance. A Karyotype was performed in 13 of the 24 cases of hyperdiploidy. None of 
these cases were found to have trisomies of chromosomes four or ten. 
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Table 3.5  
Ploidy groups according to the DNA index on flow cytometric analysis  
Group No  of patients 
Hyperdiploid >1.16 24 
Low Hyperdiploid* (1.05-1.16) 
 
Diploid* (0.95-1.05) 
 
Pseudodiploid* 
 
6 
 
42 
 
22 
*Grouped as diploid for Ploidy analysis (n=70).  
There were no hypodiploid cases 
 
 
3.2 Treatment protocol 
There were 54 children treated according to the Toronto C protocol and 46 children 
according to a modified ALL BFM 95 protocol. There was no significant difference 
between the two treatment protocols in the EFS after 5 years (p=0.8).  Eight children 
treated according to a modified ALL BFM 95 protocol were changed to a high risk 
protocol (Table 3.6). The use of a more intensive treatment protocol in these patients with 
high risk features was not significantly associated with a better outcome (p = 0.6). 
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Table 3.6  
Patients treated according to a modified high risk Berlin-Frankfurt-Munster 95 protocol 
Patient High risk criteria EFS* (months) Outcome 
Patient 1 t(9;22) 64.1 Alive and in remission 
Patient 2 t(9;22) 45.0 Alive and in remission 
Patient 3 t(9;22) 37.4 Relapse and died 
Patient 4 t(9;22) 14.4 Relapse and died 
Patient 5 t(9;22) 5.8 Alive and in remission 
Patient 6 Day 33 BM > 5% 8.2 Alive and in remission 
Patient 7 Day 8 blasts > 1 x 10 9/l 29.9 Alive and in remission 
Patient 8 Day 8 blasts > 1 x 10 9/l 6.1 Alive and in remission 
*from diagnosis 
 
 
3.3 Treatment response 
In this study the estimated EFS rate after five years was 80.8% (95% CI, 71.1%-87.6%) 
(including the ten non disease related deaths). There were 19 children who relapsed. 
Their clinical and laboratory characteristics are tabulated in Appendix C. In the children 
treated according to the Toronto C protocol, the major cause of treatment failure was 
early marrow relapse. There were five induction failures on the Toronto C protocol.  
There were no induction failures on the modified ALL BFM 95 protocol; however there 
were six early relapses (within the first year after induction therapy). Overall, most 
relapses occurred during maintenance therapy (n=eight).  
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3.4 Morphologic response to remission induction therapy 
3.4.1 Day eight prednisone response 
A PB analysis was performed in 38 patients on day eight. There was evidence of a rapid 
early response in 36 patients. The numbers were however, too small and the follow-up 
too short to predict outcome (p=0.4). 
 
3.4.2 Day 15 bone marrow analysis 
An early response to remission induction therapy was measured on BM analysis in 95 
patients. Results on day 15 were not available in three cases and two patients died prior to 
reaching day 15 of treatment.  
 
Evaluation of an early response to induction therapy on day 15 by morphologic analysis 
gave a sensitivity and positive predictive value (PPV) of 85.9% and 87.0% which was 
significantly predictive of survival. Figure 3.2 illustrates that 77 patients achieved an 
early response to therapy associated with an EFS after five years of 87.5% (95% CI, 
77.2% - 93.3%, p<0.004). An early response to therapy predicted survival in 67 of these 
patients who had not relapsed at closure of the study with an average follow-up of 62.0 
months (range 4.9 to 122.3). This contrasts to those with ≥ 5% blasts which were 
associated with an EFS after five years of 51.8% (95% CI, 21.0% - 75.8%). 
 
Relapse was not predicted in ten cases with < 5% blasts on morphologic analysis (refer to 
Table 3.8). Morphologic analysis on day 15 is often impaired by haemodilution, which 
makes it difficult to estimate reliably and reproducibly residual disease. 
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Figure 3.2.  
Kaplan-Meier estimates of event free survival for children with ≥ 5 % and < 5% blasts on 
morphologic analysis on day 15 of induction therapy 
 
 
3.4.3 Day 33 bone marrow analysis 
A BM analysis was performed in 97 patients on day 33. Results were not available in 
three patients who died prior to day 33.  
 
The day 33 analysis gave a high sensitivity and PPV (98.8% and 85.1% respectively) 
which was predictive of survival. Morphologic remission was achieved in 94 patients on 
day 33 associated with a five year EFS of 84.2% (95% CI, 77.2%-90.6%, p=0.18). 
Morphologic remission predicted survival in 80 of these patients who had not relapsed at 
closure of the study (refer to Table 3.9). 
 
0 . 0 0
0 . 1 0
0 . 2 0
0 . 3 0
0 . 4 0
0 . 5 0
0 . 6 0
0 . 7 0
0 . 8 0
0 . 9 0
1 . 0 0
0 1 2 3 4  5 6 7 8 9 1 0
Y e a r s  
D 1 5  B M < 5 %
D 1 5  B M ≥ 5 %
K a p l a n - M e i e r  s u r v i v a l  e s t i m a t e s  -  D a y  1 5  B M  
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Relapse was not predicted in 14 cases with < 5% blasts on morphologic analysis (refer to 
Table 3.9). These 14 patients relapsed at an average of 24.5 months from diagnosis 
(range 5.9 to 83.8). The day 33 morphologic analysis yielded a low specificity and 
negative predictive value (NPV) of 12.5% and 66.7% respectively. Use of morphologic 
analysis on day 33 as a single investigation risks persistent disease not being detected. 
 
On day 33, ≥ 5% blasts were detected in three BM assessments. This predicted relapse in 
two cases (at 2.2 and 3.5 months from diagnosis respectively). The other patient who was 
treated according to a high risk protocol had not relapsed at closure of the study (8.2 
month follow-up).  
  
3.5 Predictive value of minimal residual disease  
3.5.1 Minimal residual disease targets identified at diagnosis 
An IgH gene rearrangement with FR3 and/or FR2 primers was identified in 68 patients 
(81.9%) for MRD monitoring (Table 3.7). A leukemic phenotype with CD19, CD10 
and/or CD34 expression was identified in all 100 patients for follow -up of MRD. 
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Table 3.7  
Results of PCR analysis performed in 83 patients at diagnosis 
PCR result Number of patients 
FR2 monoclonal 48 
FR3 monoclonal 60 
Polyclonal 11 
No result 4 
Not done 17 
In the present study, the detection frequency of IgH gene rearrangements with FR3 primers was 72.3% versus 57.8% with 
FR2 primers at diagnosis. Follow-up was possible with at least two targets in 38 (45.8%) patients.   
 
 
3.5.2 Minimal residual disease results during treatment 
3.5.2.1 Day 15 PCR 
PCR results on day 15 were available in only 50 patients thus a direct comparison with 
the morphology findings (n=100) on day 15 was not possible.  
 
Evaluation of an early response to induction therapy on day 15 molecular analysis was 
significantly predictive of survival. There were 35 patients with no MRD on day 15 
associated with an EFS after five years of 89.3% (95% CI, 70.1% - 96.4%, p<0.02). This 
is compared to those with evidence of MRD associated with an EFS after five years of 
66.7% (95% CI, 37.5% - 84.6%) (Figure 3.3). This test predicted the survival of 32 of the 
patients (refer to Table 3.8). At the closure of the study, these patients had not relapsed 
within an average follow up of 59.2 months (range 4.9 to 108.3). The use of a simplified 
PCR assay offered a lower sensitivity (of 76.2%) as compared to conventional 
morphology on day 15. 
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Figure 3.3  
Kaplan-Meier estimates of Event Free Survival for children with and without minimal 
residual disease on PCR analysis on day 15 of induction therapy  
 
 
MRD was present in 15 patients on day 15. The presence of MRD predicted relapse in 
five patients, however there were ten patients who had not relapsed at closure of this 
study. These ten children were more likely to have favourable prognostic features when 
compared to the five patients who relapsed. The use of a simplified PCR assay was not 
predictive of relapse. 
 
There were ten patients with < 5% blasts by conventional morphology on day 15 who 
relapsed. MRD detection was performed in five of these patients and there was evidence 
of MRD in two cases. The disjoint day 15 morphologic and day 15 molecular tests did 
not add significant predictive power to the two tests taken singly (refer to Table 3.8).  
 
0 . 0 0  
0 . 1 0  
0 . 2 0  
0 . 3 0  
0 . 4 0  
0 . 5 0  
0 . 6 0  
0 . 7 0  
0 . 8 0  
0 . 9 0  
1 . 0 0  
0 1 2 3 4 5 6 7 8 9 1 0
Y e a r s
N o M R D
M R D
K a p l a n - M e i e r  s u r v i v a l  e s t i m a t e s  -  D a y 1 5  I g H  
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Table 3.8  
Comparison of Day 15 morphologic and minimal residual disease analysis  
 
 
T es ts  R e l aps ed /d i ed  
        t r u e  
Sur v i ved  
   t r u e  
T o t a l  *S ens i t i v i t y  
      ( %)  
Sp ec i f i c i t y  
     ( %)  
*PPV  
 (% )  
N PV  
 (% )  
BM  
< 5 %  
≥  5%  
 
10  
7  
 
67  
11  
 
77  
18  
    
 17  78  95  85 . 9  41 . 2  87 . 0  38 . 9  
P C R  
p o l y  
m on o  
 
3  
5  
 
32  
10  
 
35  
15  
    
 8  42  50  76 . 2  62 . 5  91 . 4  33 . 3  
FC   
<  5 %  
≥  5%   
 
7  
10  
 
40  
24  
 
47  
34  
    
 17  64  81  62 . 5  58 . 8  85 . 1  29 . 4  
*S ens i t i v i t y  an d  P PV  is  s t a t ed  i n  t e r ms  of  t h e  va r i ab l e  f or  s u r v i v a l 3  
K ey :  
PPV ,  p os i t i ve  p r ed ic t i ve  v a l u e ;                             N P V ,  n eg a t i v e  p r ed ic t i ve  va l u e ;   
p o l y ,  p o l yc l on a l ;                                                 m o n o,  m on oc l on a l   
 
 
3.5.2.2 Day 15 flow cytometry 
FC analysis performed in 81 patients on day 15 was not significantly predictive of 
outcome (refer to Table 3.8).  
 
There were 34 patients with ≥ 5% CD19/CD10 co-expressing cells. The presence of 
MRD predicted relapse in ten of these patients. There were 24 children with evidence of 
MRD, who had not relapsed at closure of the study. Use of a simplified FC assay was an 
unsatisfactory predictor of relapse on day 15 analysis.  
                                               
 
3 The Oxford Dictionary of Statistics defines sensitivity as ‘the probability of a test 
giving a correct result’. In this analysis this relates to actual survival. For example, < 5% 
BM blasts is an accurate predictor of survival (high sensitivity and PPV). However, the 
prediction of relapse or death is inaccurate (low specificity and NPV). 
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3.5.2.3 Day 33 PCR 
Molecular analysis performed in 65 patients on day 33 was not significantly predictive of 
outcome (refer to Table 3.9).  
 
MRD was present in 13 patients at the end of induction. The presence of MRD predicted 
relapse in one patient. The high percentage of false positive results made this test an 
unsatisfactory predictor of relapse, which added considerably to the cost of the day 33 
analysis (refer to Table 3.9).  
 
Table 3.9  
Comparison of Day 33 morphologic and minimal residual disease analysis  
 
T es ts  R e l aps ed /d i ed  
        t r u e  
Sur v i ved  
   t r u e  
T o t a l  *S ens i t i v i t y  
      ( %)  
Sp ec i f i c i t y  
     ( %)  
*PPV  
 (% )  
N PV  
 (% )  
BM  
< 5 %  
≥  5%  
 
14  
2  
 
80  
1  
 
94  
3  
    
 16  81  97  98 . 8  12 . 5  85 . 1  66 . 7  
P C R  
p o l y  
m on o  
 
10  
1  
 
42  
12  
 
52  
13  
    
 11  54  65  77 . 8  9 . 1  80 . 8  7 . 7  
FC   
<  5 %  
≥  5%   
 
12  
3  
 
70  
2  
 
82  
5  
    
 15  72  87  97 . 2  20 . 0  85 . 4  60 . 0  
*S ens i t i v i t y  an d  P PV  is  s t a t ed  i n  t e r ms  of  t h e  va r i ab l e  f or  s u r v i v a l  
K ey :  
PPV ,  p os i t i ve  p r ed ic t i ve  v a l u e ;                             N P V ,  n eg a t i v e  p r ed ic t i ve  va l u e ;   
p o l y ,  p o l yc l on a l ;                                                 m o n o,  m on oc l on a l  
 
3.5.2.4 Day 33 Flow Cytometry 
FC analysis was performed in 87 patients on day 33. FC analysis on day 33 was 
significantly predictive of survival (refer to Table 3.9).  
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There were < 5% CD19/CD10 co-expressing cells in 82 patients associated with an EFS 
after 5 years of  84.4% (95% CI,73.4%-91.1%, p<0.01).  This predicted survival in 70 of 
these patients who had not relapsed at closure of the study.  
 
There were ≥ 5% CD19/CD10 co-expressing cells in five patients. This predicted relapse 
in three patients. Day 33 represented the most reliable time point for distinguishing 
leukemic cells from reactive precursor B cells with limited antibody panels. 
 
The detection of MRD by limited FC offered a high sensitivity and PPV (97.2% and 
85.4% respectively), however did not significantly improve the morphological 
assessment of a response to remission induction therapy. Morphology or 
immunophenotypic analysis or a disjunction of the two were not significantly predictive 
of relapse or death.  
 
3.5.2.5 PCR prior to commencing maintenance and completion of therapy 
A molecular analysis was performed in 66 patients prior to commencing maintenance 
therapy and in 39 patients at completion of therapy (refers to table 3.10). This was not 
statistically significantly predictive of outcome. Significance was impaired by the small 
sample size.  
PCR analysis yielded a high number of false positive results on sequential follow-up and 
was therefore an unreliable predictor of relapse.  
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Table 3.10  
Results of minimal residual disease analysis performed prior to maintenance therapy and 
at completion of therapy 
 
T es ts  R e l aps ed /d i ed  
        t r u e  
Sur v i ved  
   t r u e  
T o t a l  *S ens i t i v i t y  
      ( %)  
Sp ec i f i c i t y  
     ( %)  
*PPV  
 (% )  
N PV  
 (% )  
PM  
P C R  
P ol y  
m on o  
 
 
8  
1  
 
 
53  
4  
 
 
61  
5  
    
 9  57  66  93 . 0  11 . 0  86 . 9  20 . 0  
PM  
FC   
<  5 %  
≥  5%  
 
 
8  
2  
 
 
57  
12  
 
 
65  
14  
    
 10  69  79  82 . 6  20 . 0  87 . 7  14 . 3  
 
End  
P C R  
p o l y  
m on o  
 
 
2  
1  
 
 
27  
9  
 
 
29  
10  
    
 3  36  39  75 . 0  33 . 3  93 . 1  10 . 0  
End  
FC   
<  5 %  
≥  5%  
 
 
3  
1  
 
 
43  
7  
 
 
46  
8  
    
 4  50  54  86 . 0  25 . 0  93 . 5  12 . 5  
*S ens i t i v i t y  an d  P PV  is  s t a t ed  i n  t e r ms  of  t h e  va r i ab l e  f or  s u r v i v a l   
K ey :  
PPV ,  p os i t i ve  p r ed ic t i ve  v a l u e ;                             N P V ,  n eg a t i v e  p r ed ic t i ve  va l u e ;   
p o l y ,  p o l yc l on a l ;                                                 m o n o,  m on oc l on a l   
PM ,  p r i o r  t o  m a i n t en an c e ;                                    E n d ,  en d  of  t h e r ap y  
 
 
 
3.5.2.6 Flow cytometry prior to maintenance and completion of therapy  
FC analysis was performed in 79 patients prior to commencing maintenance therapy and 
in 54 patients at completion of therapy (refers to Table 3.10). This was not statistically 
significantly predictive of outcome.  
 
As expected, the proportion of samples with the presence of MRD on FC was higher on 
day 15 than on day 33, however did not decrease thereafter at prior to maintenance. At 
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regenerative time points, such as prior to maintenance therapy, there is an increasing 
number of immature B cells which represent reactive precursor B cells. Limited 
immunophenotypic analysis did not accurately distinguish these reactive precursor B 
cells from leukaemic cells at prior to maintenance (Dworzak, et al 2002). As a result, 
there were two patients (with survivals of 36 and 20.2 months respectively) who 
demonstrated increasing numbers (≥ 5%) of CD19/CD10 co-expressing cells several 
months before morphological relapse was detectable (Figure 3.4). These cells, however, 
resembled reactive precursor B cells on limited analysis and relapse was not predicted. 
MRD on PCR analysis was not detected in one case and not performed in the other.  
 
Key: 
a. % CD19/CD10 cells at day 15  
b. % CD19/CD10 cells at day 33 
c. % CD19/CD10 cells at prior to maintenance therapy  
d. % CD19/CD10 cells at the time of morphological relapse 
 
Figure 3.4  
Detection of minimal residual disease at sequential time points in therapy by flow 
cytometry in two relapses 
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The presence of MRD on more than one occasion was a stronger predictor of relapse. In 
this study there were three patients that demonstrated MRD by FC at more than two 
sequential time points in the first six months of therapy. These patients relapsed at 6.6, 
13.4 and 48.9 months respectively after achieving morphologic remission. 
  
3.5.3 Stability of minimal residual disease targets at relapse 
BM samples at relapse were analysed in six patients with BM involvement. In only one 
of six of these patients at least one PCR target remained stable i.e., one of 11 targets. The 
false negative results at relapse are probably due to continuing rearrangements and clonal 
selection. 
  
In contrast, at the time of relapse, the immunophenotype was stable when compared to 
primary diagnosis. In all 14 relapses who achieved morphologic remission, MRD was not 
detected in the BM’s preceding relapse with limited FC. The median interval between 
these aspirations and relapse was ten months (range 5.9 – 83.8).  
 
3.6 Prognostic features 
Of the risk factors analysed, the prognostic features tabulated in Table 3.11 were 
predictive of survival. These tests gave prediction rates of EFS which were significantly 
higher than the five year EFS rate based on treatment alone. The most favourable 
subgroup was non-black females aged 2-10 years. In this group an EFS rate of 100% was 
achieved (p <0.01). 
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Table 3.11  
Significant prognostic factors predictive of survival  
 
Tests and factors predict ive 
of  survival 
EFS 
at  last 
date*  
EFS 
5 years 
 
95%  CI  
 
p-value 
Day 15 BM< 5% 
Day 15 IgH no MRD 
Day 33 %CD19/10 < 5% 
Non-b lack 
Fem ale 
Age b etween 2  and 10 years  
87.0% 
91.4% 
85.4% 
87.5% 
95.3% 
86.8% 
87.1% 
89.2% 
84.4% 
87.5% 
97.6% 
86.3% 
[76.6%,  93.1%] 
[70.1%,  96.4%] 
[73.4%,  91.1%] 
[75.4%,  93.9%] 
[84.2%,  99.6%] 
[75.1%,  92.7%] 
<0.004 
<0.02 
<0.01 
<0.01 
<0.01 
<0.02 
*  d iagnosis  to  l as t  date m ay be less  than 5 years  
 
 
A Cox proportional hazards model was used to compute the ratio of relapse or death in 
the entire cohort (Table 3.12).  
 
 
Table 3.12  
Multivariate Cox Regression analysis  
 
Tests and factors predict ive 
of  re lapse or  death 
Hazard 
rat io  based 
on a  Cox 
regression 
 
95% CI  
 
p-value 
Day 15 BM ≥  5% 
Day 15 IgH  MRD 
Day 33 %CD19/10 ≥  5% 
Black  
Male  
Age < 2  and >10 years  
3 .0  
4 .4  
8 .8  
3 .4  
14.8  
2 .9  
[1 .1 ,  8 .4 ]  
[1 .0 ,  18.6 ]  
[2 .4 ,  32.1 ]  
[1 .3 ,  9 .0 ]  
[1 .9 ,  11 .3 ]  
[1 .1 ,  7 .4 ]  
<0.004 
<0.02 
<0.01 
<0.02 
<0.01 
<0.03 
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4. DISCUSSIONS AND CONCLUSION 
This is a single centre account of the treatment outcome and prognostic factor analysis in 
a series of 100 children diagnosed with Precursor B cell ALL in the modern treatment 
era. The following discussion has been formulated according to the research questions 
outlined in section 1.3. 
 
4.1 Treatment outcome 
Treatment was based on modifications of the widely used BFM treatment regimen, 
namely Toronto C and ALL BFM 95 protocols (Schrappe 2004). Preceding this analysis, 
studies demonstrated a poor survival rate in South African children (MacDougall 1985, 
Wessels, et al 1997). All children in this study were thus assigned to augmented 
treatment protocols, which resulted in a significantly improved outcome (a five year EFS 
of 80.8%). This is consistent with reports from large multi-centre trials (Pui and Evans 
1998). Although there was no further increase in EFS after five years with introduction of 
prednisone monotherapy with the ALL BFM 95 protocol, there was evidence of an 
improved response to induction therapy. 
 
4.2 Clinical Prognostic Features 
The clinical features, race and age emerged as significant prognostic factors in preceding 
South African studies. In this study, black males aged < 2 and > 10 years were associated 
with a poor prognosis. In multi-centre studies, in the modern treatment era, the predictive 
value of clinical features has been lost. The combination of these features in South 
African children may represent a distinct subgroup at risk for poor survival and relapse. 
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With treatment intensification and improved access to treatment4 in this recent study, 
survival rates across racial groups have increased significantly. Previously an EFS after 
five years of 32% and 72% respectively were reported in black and white children with 
ALL in Johannesburg between 1974 and 1982 (Macdougall, et al 1986). In this study, 
black and white children achieved an EFS after five years of 68.9% (95% CI, 49.7%-
82.1%) and 86.1% (95% CI, 71.3%-93.6%) respectively.  
 
Even with equal access to treatment, black children continue to fare poorly, whereas 
outcomes for mixed and Asian children did not differ significantly from those of white 
children. This is consistent with the findings of the recent Paediatric Oncology Group 
(POG) and Children’s Cancer Group (CCG) reports which showed an EFS after five 
years of 61% and 69% respectively (Bhatia, et al 2002, Pollock, et al 2000). In this study, 
black South African children were more likely to have unfavourable prognostic features 
than white children. However on multivariate analysis, these features did not explain the 
poor survival rates in black children. These findings suggest that other risk factors exist 
in the tumour biology or treatment response of black children, which confers a worse 
outcome (Kadan-Lottick, et al 2003). Recently the presence of genetic polymorphisms 
affecting drug metabolism of methotrexate and 6-MP have been described in black 
patients (Pui, et al 2004a). Future studies will demonstrate the predictive value of host 
                                               
 
4 Patients with poor socio-economic circumstances were institutionalised for the duration 
of their therapy to ensure compliance, completion of treatment and access to routine 
follow-up.  
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genetic features. In this way pharmocogenetic features at presentation can be used to risk 
assign treatment groups.  
Contrary to these reports, a single institution study indicated that with equal access to 
treatment black children with ALL can achieve high cure rates (five year EFS of 80.7%) 
(Pui, et al 2003). Black children, however, represented a small proportion of this study. 
 
4.3 Laboratory Prognostic Features 
In the case of WCC, the presence of a t(9;22) or t(12;21) and Ploidy there was either 
insufficient numbers tested or the results were not significantly predictive of outcome.  
 
4.4 Predictive value of genetic features 
In order to improve the overall survival rate, therapy is intensified according to the 
genetic features of the leukaemic blasts. Published series such as the XIIIB Study have 
demonstrated the independent prognostic significance of the BCR-ABL or MLL-AF4 
gene rearrangements (Pui, et al 2004c).  
 
In this study, the presence of the BCR-ABL rearrangement was associated with a poor 
EFS after five years of 41.7% (95% CI, 5.6%-76.7%; p=0.1). This was not statistically 
significant because of the small sample size. Children with a Ph chromosome were more 
likely to present at an older age with a higher WCC.  This is in contrast to TEL-AML1 
positive ALL cases which were more likely to be characterised by favourable presenting 
features. The presence of the TEL-AML1 rearrangement was associated with an 
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improved five year EFS, however in keeping with recent reports; this was not predictive 
of survival (Harbott, et al 1997, Satake, et al 1997, Seeger, et al 1998). 
 
The presence of chromosomal translocations also represents a stable target for the 
detection of MRD by reverse transcriptase (RT)-PCR amplification in 23 of the children 
in this study population (de Haas, et al 2000, Markus, et al 2006, Satake, et al 1997, 
Seeger, et al 1998). Although this would only be applicable in a small percentage of 
ALL’s (BCR-ABL transcripts were detected in six cases and TEL-AML1 transcripts in 
17 cases in this study), it is a less complex method than PCR analysis of gene 
rearrangements which is also limited by clonal evolution. 
 
4.5 Predictive value of Treatment response 
4.5.1 Day eight prednisone response 
In the case of the day eight PB response to prednisone, there were insufficient numbers 
tested to determine its predictive value.  The leukemic cells in 92.1% of the children in 
this study demonstrated evidence of a sensitivity to prednisone therapy. 
 
4.5.2 Day 15 analysis 
The evaluation of an early response to therapy as determined by morphologic analysis of 
the day 15 BM identified a subgroup of patients with an ultra fast response to remission 
induction therapy. This was associated with a favourable outcome. This test gave a 
prediction rate of EFS which was significantly higher than the five year EFS rate based 
on treatment alone.  
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Use of a simplified PCR method on day 15 did not significantly improve the 
morphological assessment of an early response to remission induction therapy. There was 
no significant increase in the prediction of EFS by a combination of the two tests. Neither 
test was significantly predictive of relapse or death. Limited FC was an unsatisfactory 
predictor of outcome.  
 
4.5.3 Day 33 analysis 
Treatment response, according to the modified ALL BFM 95 protocol, is guided by 
morphologic remission status on day 33. This time point offered the highest sensitivity 
(98.8%) which was predictive of survival.  
 
Limited FC evaluation of a response to induction therapy did not add to the morphologic 
assessment. However, day 33 represented the most significant time point for performing 
limited FC because of the presence of exclusively mature B cells demonstrated early 
during treatment. Patients with ≥ 5% CD19/CD10 co-expressing cells on limited FC had 
a hazards ratio (HR) of 8.8 (95% CI, 2.4-32.1; p=0.01). Molecular analysis did not 
significantly improve the day 33 analysis. 
 
4.6 Minimal Residual Disease  
Routine use of MRD monitoring is limited by the complexity, technical expertise and 
cost of the assays. In order to extend the benefits of MRD detection to most South 
African children with Precursor B cell ALL we had instituted relatively simple and 
inexpensive PCR and FC assays. Both techniques have been employed for the detection 
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of MRD as reports in the literature have indicated that these two tests should be viewed 
as complementary to each other in view of their respective limitations (Kerst, et al 2005, 
Pui, et al 1999).  
 
The panel of limited antibodies used to study MRD by FC allowed monitoring of 100% 
of patients, whereas PCR based on IgH primers did not detect 20% of rearrangements at 
diagnosis for follow-up of MRD. Detection of rearrangements was restricted by the panel 
of primers used. This is consistent with the findings of previous studies which employed 
simplified PCR techniques (Potter, et al 1993) (Nizet, et al 1991).  
 
In this study, the detection of MRD by simplified PCR and FC assays did not provide 
additional information when compared to conventional morphologic assessment of 
treatment response. As indicated above, use of a simplified PCR and FC assay did not 
significantly improve the morphological findings of an early response to therapy but did 
add to the cost of the assessment of residual disease5. Further, assessment of MRD at 
later time points in treatment did not emerge as a significant predictor of subclinical 
relapse. 
 
                                               
 
5 The cost of a routine BM analysis in 2007 was R275.00. Complementary PCR and 
limited FC was performed at an additional cost of R467.00 per primer and R165.00 per 
monoclonal antibody. This added an additional cost of at least R1429.00 to the analysis at 
each time point. 
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4.6.1 Limitations of a simplified PCR assay 
MRD was detected via a qualitative nested PCR using four consensus primers. This is a 
rapid and simple method compared to other more complex methods which are based on 
sequencing and the use of patient-specific probes. Although more complex methods are 
labour intensive, a specificity of 100% can be routinely achieved (Panzer-Grumayer, et al 
2000). In this study, the specificity never exceeded 62.5%. This can be explained on the 
basis of the limited panel of primers used and/or improper primer annealing. At least two 
PCR targets are required per patient for follow-up of MRD because of ongoing secondary 
rearrangements (Beishuizen, et al 1994, Szczepanski, et al 2002). In this study, 
subclinical relapse was not detected in the six available samples. MRD PCR targets 
present at diagnosis were preserved at relapse in only one patient. In the other five, 
failure to detect relapse may have been associated with loss of the IgH gene 
rearrangement. 
 
Use of a simplified PCR assay yielded a lower sensitivity as compared to morphologic 
analysis. The day 15 analysis gave the lowest sensitivity (76.2%). This is most likely due 
to the increased presence of non-viable cells during induction therapy as studies using 
specific PCR techniques also report a low sensitivity (Panzer-Grumayer, et al 2000). 
Another cause to be considered was the possibility of contamination because the same 
sets of primers were used for different patients. Negative controls are however included 
with every batch of samples analysed to limit this risk. The inability to differentiate 
oligo-clonal from monoclonal populations at diagnosis is more likely. Another limitation 
of this PCR assay was the use of gel electrophoresis to resolve the different sized 
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amplicon products. This simplification allows for easier routine detection, however 
polyclonal background levels further limit the sensitivity (one leukaemic cell per 103 
normal bone marrow cells). 
 
Comparisons of our results on MRD to other clinical trials are difficult as a result of the 
different techniques employed. Despite this the detection of MRD emerges as a 
significant predictor of outcome in all studies. This indicates that a uniform method for 
the detection of MRD is not required, provided the method used can achieve a sensitivity 
of more than one leukemic cell per 104 normal bone marrow cells (Brisco, et al 1994, 
Foroni, et al 1999, Wasserman, et al 1992).  
 
4.6.2 Limitations of a simplified Flow cytometry assay 
Use of extensive panels for follow-up of aberrant expression limits the routine application 
of FC for MRD follow-up. Most of the reports in the literature are based on aberrant 
expression (Campana and Coustan-Smith 2004). Other authors have reported the value of 
a simplified FC assay based on CD19, CD10 and/or CD34 expression using standardised 
panels (Coustan-Smith, et al 1998, Coustan-Smith, et al 2006, Farahat, et al 1998). This 
has been shown to be a simple and sensitive technique which can discriminate between 
leukaemic and reactive precursor B cells at early time points during treatment.  
 
As demonstrated, this FC method reliably discriminated between leukaemic cells and 
normal cells at day 33 of treatment. Regenerative time points (prior to maintenance) were 
characterised by a limited sensitivity in a high proportion of cases because of the 
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presence of immature B cells which resemble leukaemic cells immnophenotypically 
(Dworzak, et al 2002). 
 
The analysis of MRD at a single time point was not sufficient for recognition of patients 
with poor prognosis as well as patients with good prognosis in this study. In keeping with 
the findings in the literature, the presence of MRD at more than two sequential time 
points was a more reliable predictor of relapse (Dworzak, et al 2002).  
 
MRD was not detected in the BM’s performed prior to relapse in the 14 relapses studied. 
This can be explained on the basis of a recent study which showed that MRD could be 
detected by FC (at a level of >0.1% nucleated cells) in aspirates performed within three 
months of relapse; however not after six months (Dworzak, et al 2002). Most relapses 
occurred during maintenance therapy and BM’s were performed more than six months 
prior to relapse.  More frequent sampling of patients may be needed, especially in the 
first two years of treatment, in order to detect relapse. However continuous BM 
monitoring is a traumatic experience for a child. The findings of this study indicate that 
measurement of an early treatment response represents a more reliable predictor of 
survival. In addition, assessment of a response to induction therapy provides the 
possibility for early treatment intervention (Nachman, et al 1998). 
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4.7 Limitations of the study 
There are some limitations in this study which should be considered: 
 
1. Prognostic features used to risk assign therapy namely, the day eight PB response to 
prednisone therapy and the genetic features of the leukaemic blasts did not reach 
statistical significance in this study. However, these findings were limited by the 
small number of patients studied on the ALL BFM 95 protocol (n=46). 
 
2. This study was performed retrospectively and thus PCR and FC results were not 
available in all patients at all time points for the assessment of MRD. (In most of 
these instances the tests were not performed because of cost constraints or limited 
sample material). Direct comparison with the morphology findings was thus not 
possible. In addition, the panel of FC markers performed at each time point was not 
standardized. Studies comparing FC and PCR have indicated that the two methods 
generally yield concordant results (Neale, et al 1999). This finding could not be 
confirmed in this study. 
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4.8 CONCLUSION AND RECOMMENDATIONS 
The results of this study suggest that children of different racial, gender and age groups 
with Precursor B cell ALL vary in their survival despite treatment intensification. This is 
important as these factors are not normally considered when risk assigning patients 
according to the current treatment protocol. WCC, previously predictive of outcome in 
South African studies, has been replaced by measurement of an early treatment response 
at day 15. Assessment by morphology offers a limited sensitivity because the presence of 
< 5% blasts accurately predicted survival in only 85.9% of patients tested on day 15. 
MRD techniques are required to improve the predictive value of the morphologic 
assessment. However analysis of MRD as detected by simplified PCR and FC assays did 
not significantly improve the assessment of conventional morphology.  The ALL BFM 
95 criteria namely; an early response to prednisone therapy and the genetic features of the 
leukaemic blasts which are used to risk assign patients, did not emerge as important 
variables in this study. However it must be emphasised that there were too few cases to 
assess prognostic significance. 
  
In a low resource setting, the challenge is to design easy and cost effective methods in 
order to identify all patients at risk for relapse. In view of the results of this analysis, the 
following measures have been introduced in order to improve the current PCR assay at 
the NHLS:  
 
In an attempt to standardise the detection of MRD, the primer sets designed by the 
European BIOMED-2 collaborative study group (van Dongen, et al 2003) were 
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implemented at the NHLS, Johannesburg in 2007.  This InVivoScribe Technologies’ 
IdenticloneTM PCR IgH assay combines multiple consensus primers that target FR2, FR3 
and framework region one (FR1) within the variable and conserved joining regions, as 
well as the diversity and joining regions and of the IgH chain locus (Figure 4.1).  
 
 
 
 
Figure 4.1  
Immunoglobulin Heavy chain gene rearrangements  
The arrows represent the positions of the primers that target the conserved FR1-3 of the 
variable (VH) and the conserved joining (JH) region (InVivoScribe Technologies’ 
IdenticloneTM PCR IgH package insert). 
 
 
If no IgH rearrangement is detected, screening for other clonality markers including Ig 
kappa light chain (IgK), Ig lambda light chain (IgL), TCR beta (TCRB), TCR gamma 
(TCRG) and TCR delta (TCRD) genes can be performed. This will increase the 
percentage of patients covered to > 95%. This will also help to detect all sub clones at 
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diagnosis and to monitor patients with at least two targets to prevent false negatives 
during follow-up as a result of continuing secondary rearrangements (Beishuizen, et al 
1994, Szczepanski, et al 2002, van Dongen, et al 1998).  
 
The PCR products will be visualised by an alternative method to gel electrophoresis 
using capillary electrophoresis which detects differential fluorescence. In this way the 
amplicon products are differentially detected with primers conjugated with fluorescent 
dyes corresponding to different targeted regions (van Dongen, et al 2003).This method 
eliminates the use of carcinogens such as Ethidium bromide.  
 
Differential detection allows for accurate, reproducible and objective interpretation. In 
addition, this can be used to provide a semi-quantitative assessment of tumour reduction 
(Figure 4.2). This is a more affordable alternative to sequencing the initial product and 
designing allele specific primers (Pongers-Willemse, et al 1999). In this way an increased 
level of MRD during early therapy and/or persistent MRD during the course of treatment 
will provide a more reliable predictor of relapse. 
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Key: 
Panel 1: 100% alternative clonal control 
Panel 2: 100% recommended clonal control 
Panel 3: 10% dilution of recommended clonal control 
Panel 4: polyclonal control 
(InVivoScribe Technologies’ IdenticloneTM PCR IgH package insert) 
 
Figure 4.2  
Differential fluorescent detection of the amplicon products within framework region one 
 
 
For future MRD detection at the NHLS, the decision to use either one method or the 
concurrent use of PCR and FC may be determined by cost. The cost of MRD follow-up 
with the above PCR assay will be increased approximately three fold. 
 
Attempts have also been made to standardise the detection of MRD by FC. Aberrant 
immunophenotypic profiles have been previously described by the European BIOMED-1 
collaborative study group (Lucio, et al 2001). This assay uses a combination of five triple 
 5 4
monoclonal antibody combinations, namely TdT/CD10/CD19; CD10/CD20/CD19; 
CD34/CD38/CD19; CD34/CD22/CD19 and CD19/CD34/CD45. The pattern of antigen 
expression allows for accurate discrimination of 98% of Precursor B-cell ALL cases at 
diagnosis which can be used for follow-up. On multi centre analysis aberrant expression 
was identified with at least two and often three of the triple monoclonal antibody 
combinations per case.  
 
This profile does not routinely include cross lineage T cell (CD2 and CD7) or myeloid 
(CD13, CD33, CD15 and CD65) expression. According to the recommendations, these 
should only be performed in select cases where applicable. Implementation of this 
standardised FC profile could allow for more accurate assessment of MRD. This will also 
be of value at regenerative time points to distinguish leukaemic cells from reactive 
precursor cells without substantially increasing the cost of the assay. 
 
Better predictors of outcome are needed to identify patients requiring aggressive therapy 
and to avoid over treating those patients likely to do well. Further development in the 
fields of molecular diagnostics and the detection of MRD are essential in order to refine 
therapy, in particular for patient subgroups (black race and male gender) with divergent 
results. 
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Appendix A 
Toronto C high risk Treatment Protocol  
 
Ind u ct i on  t her a py  ( ~4  w k)  Pr ed n is on e  p o  q  d a y  
V i nc r is t i n e^  I V I  q  w eek  
D aun or u b ic in *  I V I  q  w eek  
L ’as p ar ag i n as e  I V I  x  9  d os es  
C N S T r ea tm e nt  (~ 4  w k)  IT  M et h o t r ex a t e  x  3  d os es  
IT  A r a -C  x  1  d os e  
C N S d is eas e-T r i p l e  IT  q  w eek  
C on s o l i d at i on  t her a py   
P h as e  I I  
 
 
 
 
 
P h as e  I I I -C N S In t e ns i f ic at io n  
 
 
 
 
 
 
P h as e  IV  R e- i nd u ct i on /R e- i n t en s i f i c at i on  
I  
 
 
 
I I  
 
C yc l op h os p h am id e  IV I  x  2  d os es  
A r a -C  IV I  x  4  d os es  q  w eek  
6 - MP  p o  q  d a y  
IT  M et h o t r ex a t e  q  w e ek  
 
 
6 - MP  p o  x  3 5  d a ys  
H i gh  d os e  M et h o t r e xa t e  x  3  d os es  
<  6  y ear s :  IT  M eth o t r ex a t e  q  w eek  
               
>  6  y ear s :  1 8  G y c r an i a l  i r r ad i a t i on  
 
 
D exam et h as on e  p o  q  d ay  
V i nc r is t i n e  I V I  q  w eek  
Adr i am yc in  I V I  q  w eek  
L ’as p ar ag i n as e  I M I  x  4  d os es  
C yc l op h os p h am id e  IV I  x  1  d os e  
A r a -C  IV I  x  4  d os es  q  w eek  x  2  
6 -T h i og u an i n e  p o  1 4  d a ys  
IT  M et h o t r ex a t e  q  w e ek  x  2  
 
M aint en an c e t he ra py  ( 3  mo nt hs ,  t o  co nt in ue  
unt i l  3  y e ar s  f r o m d i ag no s is )  
Pr ed n is on e  p o  x  5  d ays  4  w eek l y  
V i nc r is t i n e  I V I  x  4 w eek l y  
M et h o t r e xa t e  p o  w eek l y /  IV I  2 w eek l y  
IT  M et h o t r ex a t e  x  1  d os e  
 
*c om m enc ed  on  D ay 0  of  i n duc t i on  t h er ap y   
K ey :  
IT ,  i n t r a t h ec a l ;                                                  p o ,  p er  os ;   
IV I ,  in t r a ven ous ;                                               C N S ,  c en t r a l  n e r v ous  s ys t em  
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Appendix B 
Modified Berlin-Frankfurt-Munster 95 Medium Risk Treatment Protocol 
Ind u ct i on  t her a py  ( ~4  w k)  Pr ed n is on e  p o  q  d a y  
V i nc r is t i n e  I V I  q  w eek  
D aun or u b ic in  I V I  q  w eek  
L ’as p ar ag i n as e  I V I  x  9  d os es  
C N S T r ea tm e nt  (~ 4  w k)  IT  M et h o t r ex a t e  x  3  d os es  
IT  H ydr oc or t i s on e  x  3  d os es   
IT  A r a -C  x  1  d os e  
C N S d is eas e-T r i p l e  IT  q  w eek  
C on s o l i d at i on  t her a py   
P h as e  I I  
 
 
 
 
 
P h as e  I I I -C N S In t e ns i f ic at io n  
 
 
 
 
 
 
P h as e  IV  R e- i nd u ct i on /R e- i n t en s i f i c at i on  
I  
 
 
 
I I  
 
C yc l op h os p h am id e  IV I  x  2  d os es  
A r a -C  IV I  x  4  d os es  q  w eek  
6 - MP  p o  q  d a y  
IT  M et h o t r ex a t e  q  w e ek  
IT  H ydr oc or t i s on e  q  w e ek  
 
6 - MP  p o  x  3 5  d a ys  
H i gh  d os e  M et h o t r e xa t e  x  3  d os es  
<  6  y ear s :  IT  M eth o t r ex a t e  q  w eek  
              IT  H ydr oc or t i s on e  q  w e ek  
>  6  y ear s :  1 8  G y c r an i a l  i r r ad i a t i on  
 
 
D exam et h as on e  p o  q  d ay  
V i nc r is t i n e  I V I  q  w eek  
Adr i am yc in  I V I  q  w eek  
L ’as p ar ag i n as e  I M I  x  4  d os es  
C yc l op h os p h am id e  IV I  x  1  d os e  
A r a -C  IV I  x  4  d os es  q  w eek  x  2  
6 -T h i og u an i n e  p o  1 4  d a ys  
IT  M et h o t r ex a t e  q  w e ek  x  2  
IT  H ydr oc or t i s on e  q  w e ek  x  2  
 
M aint en an c e t he ra py  ( 3  mo nt hs ,  t o  co nt in ue  
unt i l  3  y e ar s  f r o m d i ag no s is )  
Pr ed n is on e  p o  x  5  d ays  4  w eek l y  
V i nc r is t i n e  I V I  x  4 w eek l y  
M et h o t r e xa t e  p o  w eek l y /  IV I  2 w eek l y  
IT  M et h o t r ex a t e  x  1  d os e  
IT  H ydr oc or t i s on e  x  1  d os e  
 
K ey:  
IT ,  i n t r a t h ec a l ;                                                    p o ,  p er  os ;   
IV I ,  in t r a ven ous ;                                                 C N S ,  c en t r a l  n e r vou s  s ys t em  
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Appendix C: Clinical and laboratory characteristics of the 19 patients who relapsed in this study 
Pat ie nt  R e mi s si on  Day  
33  
T reat m en t  
G rou p  
A ge  R a ce  G en d er  WC C  
(x 10 9 / l )  
G en et ic s  P lo idy  EFS  
(m ont h s)  
P at i en t  1  
 In d uc t i on  f a i l u r e  T or on t o  C  >1 0  w h i t e  m a l e  <5 0  t (1 2 ;2 1)  d i p l o i d  0  
P a t i en t  2  
 In d uc t i on  f a i l u r e  T or on t o  C  <2  b l ac k  m a l e  <5 0  N ot  d on e  d i p l o i d  0  
P a t i en t  3  
 In d uc t i on  f a i l u r e  T or on t o  C  <2  w h i t e  f em a l e  <5 0  N ot  d on e  d i p l o i d  0  
P a t i en t  4  
 In d uc t i on  f a i l u r e  T or on t o  C  >1 0  b l ac k  m a l e  <5 0  t (1 2 ;2 1)  d i p l o i d  0  
P a t i en t  5  
 In d uc t i on  f a i l u r e  T or on t o  C  2- 10  as i an  m a l e  >5 0  t (9 ; 22)  d i p l o i d  0  
P a t i en t  6  M or ph o l og ic  r emis s i on   T or on t o  C  2 - 10  b l ac k  m a l e  <5 0  N ot  d on e  d i p l o i d  31 . 8  
P a t i en t  7  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  2- 10  w h i t e  m a l e  <5 0  N ot  d e t ec t ed  h yp er d i p l o i d  24 . 1  
P a t i en t  8  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  >1 0  b l ac k  m a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  11 . 5  
P a t i en t  9  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  2- 10  w h i t e  m a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  50 . 1  
P a t i en t  1 0  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  2- 10  b l ac k  m a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  7 . 7  
P a t i en t  1 1  M or ph o l og ic  r emis s i on   BF M 9 5-H ig h  2 - 10  b l ac k  m a l e  <5 0  t (9 ; 22)  d i p l o i d  37 . 4  
P a t i en t  1 2  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  <2  w h i t e  f em a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  7 . 3  
P a t i en t  1 3  M or ph o l og ic  r emis s i on   BF M 9 5-H ig h  >1 0  b l ac k  m a l e  >5 0  t (9 ; 22)  d i p l o i d  14 . 4  
P a t i en t  1 4  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  2- 10  b l ac k  m a l e  <5 0  N ot  d e t ec t ed  h yp er d i p l o i d  5 . 7  
P a t i en t  1 5  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  <2  w h i t e  m a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  20 . 2  
P a t i en t  1 6  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  2- 10  b l ac k  m a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  7 . 7  
P a t i en t  1 7  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  <2  mi x ed  m a l e  <5 0  N ot  d e t ec t ed  d i p l o i d  36 . 0  
P a t i en t  1 8  M or ph o l og ic  r emis s i on   T or on t o  C  2 - 10  b l ac k  m a l e  <5 0  N ot  d on e  h yp er d i p l o i d  83 . 5  
P a t i en t  1 9  M or ph o l og ic  r emis s i on   
BF M 9 5-
M ed i u m  2- 10  b l ac k  m a l e  N o r es u l t  N ot  d on e  d i p l o i d  6 . 0  
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Appendix D 
Protocol 
The clinical significance of current laboratory and prognostic indicators in the 
management of South African children with Precursor B cell Acute Lymphoblastic 
Leukaemia 
  
Introduction  
Approximately 15 new paediatric cases of Acute Lymphoblastic Leukaemia (ALL) are 
diagnosed and treated annually at Johannesburg General Hospital. ALL is the most 
common childhood cancer(Pui, et al 1995). ALL is sub-typed (immunophenotypically) 
into B-cell ALL, Precursor B cell ALL and T-cell ALL. Precursor B cell ALL is the most 
common childhood subtype, which accounts for ~84% of cases (Camitta BM 1997). With 
advances in diagnosis and management, children diagnosed with Precursor B cell ALL 
achieve a five year event free survival (EFS) of ~80% in large clinical trials (Pui and 
Evans 1998, Silverman, et al 2001).  
 
Improvements in childhood ALL survival can be attributed to the identification of various 
risk factors which can predict outcomes (Kersey 1997). Current treatment protocols use 
clinical and laboratory prognostic features at diagnosis to help identify patients who need 
additional and more aggressive therapy. In this way only high risk cases are treated 
intensively, with less toxic therapy reserved for low risk cases (Friedmann and Weinstein 
2000). 
 
At Johannesburg Hospital, the Paediatric Oncology Unit have adopted treatment 
protocols from large co-operative trials. From January 1997 to November 2001, 
Precursor B cell ALL cases were treated according to the Toronto C protocol. 
Subsequently in December 2001, the modified ALL Berlin-Frankfurt-Munster (BFM) 95 
protocol was introduced and continues to be used to date.  
 
The modified BFM 95 protocol classifies patients into standard, medium and high risk 
groups on the basis of (Schrappe, et al 2000):  
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1. The genetic features of the leukaemic blast cells (namely the presence of t (9; 22)/ 
BCR-ABL rearrangement, or a t (4; 11)/MLL-AF4 rearrangement, associated 
with a poor prognosis). 
2. An early response to remission-induction treatment as determined by the day 
eight prednisone response and the achievement of morphologic remission 
(defined as < 5% blasts) on day 33 of induction treatment. 
 
Traditionally, studies have identified over 50 clinical and laboratory markers which 
correlate significantly with prognosis (Donadieu, et al 1998).  The following have 
been most consistently associated with a favourable outcome: a low white cell count 
(WCC) count of < 50 x 10 9/l, a presenting age of 1-10 years, female gender, white 
and Asian race groups and hyperdiploidy (DNA index >1.16) (Pui, et al 1990, Smith, 
et al 1996). However the prognostic significance of these features has been abolished 
with improvements in therapy. More recently, treatment protocols such as BFM 95 
are guided by molecular genetic findings (Pui 2000, Rubnitz, et al 1997)and 
remission status (Campana and Pui 1995). These have been shown to predict more 
accurately the outcome rather than presenting clinical features (Pui, et al 2004).  
 
Seventy five percent of childhood ALL cases have specific genetic abnormalities with 
therapeutic and prognostic significance at presentation (Pui, et al 1990).   
 
The effectiveness of therapy and impending relapse in patients is determined by bone 
marrow morphology at specific time points during treatment. Patients with < 5% 
lymphoblasts on bone marrow morphologic analysis are said to be in morphologic 
remission. However estimates by conventional morphology have limited sensitivity 
and accuracy, as even in morphologic remission patients may still have as many as 
1010 leukaemic cells in the marrow. This is responsible for relapse in 15-20% of cases 
(Campana and Pui 1995).  
 
More sensitive and specific methods were developed to assess early treatment 
response. Such methods measure minimal residual disease (MRD), which is defined 
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as the lowest level of detectable disease during morphologic remission. MRD 
detection in ALL patients is most frequently performed by multiparameter flow 
cytometry of aberrant immunophenotype (Coustan-Smith, et al 2000) or polymerase 
chain reaction (PCR) (Cave, et al 1998) since either method is reported to achieve a 
s e n s i t i v i t y  o f  0 . 01 %.  
 
Flow cytometry analysis is used to type leukaemic cells by defining their cell surface 
antigen (Ag) expression. Abnormal Ag expression on ALL blasts and abnormal 
pattern of expression distinguish leukaemic cells from normal lymphoid cells. 
 
MRD detection by PCR targets clonal immunoglobin (IgH) and T cell receptor (TCR) 
gene rearrangements and fusion genes. While only 30-40% of ALL patients have 
specific chromosomal aberrations with well-defined breakpoint fusion regions, 
virtually all patients (> 95%) have rearranged IgH genes.  
 
The process of IgH and TCR rearrangement gives rise to a unique rearrangement in 
each B and T cell respectively during normal lymphocyte development. 
Rearrangement of IgH involves recombination of one of approximately 200 germline 
variable (V) segments, 30 diversity (D) segments, and 6 joining (J) segments. Further 
variability is generated at the V-D and D-J junctions by base removal (by 
exonucleases) and random addition of ‘N’ nucleotides (by TdT). This process 
generates a hypervariable sequence known as the complementarity-determining 
region III (CDRIII) of the IgH, which characterizes a given B-cell or B-cell clone.  
 
This sequence can be amplified by PCR using consensus primers to conserved areas 
of the 5’V region and 3’J region which flank the CDR-III region. This represents a 
clonal marker specific for the patient’s disease. In a research setting a patient specific 
primer is designed from this unique sequence for follow up MRD assessment 
(Szczepanski, et al 2002). 
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Patients who achieve molecular or immunophenotypic remission (< 10-4 leukaemic 
BM cells) after induction therapy have a significantly more favourable prognosis 
(Cave, et al 1998). MRD detection has thus been incorporated into many current risk 
classification systems 18.  
 
In our unit, complementary use of PCR (of IgH gene rearrangements) and limited 
flow cytometry is performed with every bone marrow examination at specific time 
points during therapy. PCR follow-up is however only performed if an IgH 
rearrangement can be amplified at diagnosis using FR3/FR2 primers. This was 
initiated in 1996 on the basis of available technology and cost considerations. The use 
of multiple approaches is desirable so as to increase the number of patients studied 
and to minimize the limitations of individual methods (Pui and Campana 2000).  
 
The detection of MRD is currently not used to guide therapy in our unit as the clinical 
significance of MRD and its predictive value in relation to other prognostic features 
of ALL has never been formerly assessed.   
 
In a low resource setting such as South Africa, the monitoring tests employed to 
detect MRD, have been modified as a result of technical and financial constraints. 
The sensitivity of MRD detection by flow cytometry in our unit is approximately 1%, 
as only 10 000 events are counted per sample (FACS CALIBUR BD) and limited 
panels of markers are used for follow up analysis.  
 
The IgH rearrangements are currently being detected via a qualitative nested PCR 
assay using 4 consensus primers. This allows detection of 65-75% of     monoclonal 
populations (Reed, et al 1993). Gel electrophoresis is being used to resolve the 
different sized amplicon products. However, an alternative method using differential 
fluorescence detection with primers conjugated with fluorescent dyes corresponding 
to different targeted regions will be available in early 2007.  
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It is thus important to assess whether these modified tests are sensitive and specific 
enough to detect relapse in a disease with such a high survival rate.  
 
Study objectives  
1. To characterise and assess the prognostic value of clinical (gender, age, race 
and treatment protocol) & laboratory ( white cell count, ploidy, FISH and 
cytogenetic findings) risk factors in our patient population diagnosed with 
Precursor B cell ALL 
 
2. To assess whether treatment response as measured by an early response to 
therapy and the detection of MRD effectively predicts relapse and/or 
determines outcome in our patient population diagnosed with Precursor B cell 
ALL. An early response to remission-induction treatment will be determined 
by the day eight prednisone response and the achievement of morphologic 
remission (defined as < 5% blasts) on day 15 and 33 of induction treatment. 
The presence of MRD will be measured by simplified PCR for IgH gene 
rearrangements and Flow Cytometry at sequential time points during therapy, 
namely at presentation, at day 15 of induction therapy, at day 33 of induction 
therapy, prior to commencing maintenance therapy and at completion of 
therapy.  
 
            Methodology  
 
This is a retrospective record review of the presenting features and clinical 
outcome of therapy of all (a minimum of 100 cases) of Precursor B cell ALL 
diagnosed and completing treatment at the Johannesburg Hospital Paediatric 
Oncology Unit (Ward 294) from 1997 to date. 
 
The following data will be collected from patient clinic files and/ or the NHLS 
computer database: 
1. Patient demographics (Age, gender, race) 
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2. B-cell ALL subtypes (null, precursor, mature B-cell ALL) 
3. Treatment protocol 
4. Survival data 
5. White Cell Count at presentation 
6. FISH for Ph chromosome/ t(9;22), TEL-AML1/ t(12,21), and MLL-AF4/ 
t(4,11) and Cytogenetic findings at disease presentation  
7. Day eight peripheral blood count/prednisone response 
8. PCR for IgH gene rearrangement and Flow Cytometry results at diagnosis 
and specific time points during treatment 
 
This information will be useful in assessing: 
1. The clinical use of PCR for IgH gene rearrangement and Flow Cytometry at 
specific time points during treatment to detect the presence of minimal residual 
disease. 
2. The predictive value of an early response to remission-induction treatment. 
3. Clinical and laboratory prognostic factors predictive of outcome. 
 
This is a retrospective study, and the potential biases include lack of randomisation and 
small sample size. Complete data sets on all patients to be studied are readily available 
from patient clinic files and/ or the NHLS computer database. However specific tests may 
not have been performed on a subgroup of patients because of cost constraints or limited 
sample material. In addition follow-up of MRD at all time points during therapy will not 
be possible in patients who have not completed therapy at the time of closure of this 
study. 
 
Data analysis    
Data will be recorded in EXCEL. Data will be presented as numbers (frequency).Data 
will be analysed in Stata 9.2 software. Survival rates will be estimated by the Kaplan-
Meier method. The log-rank test will be used to assess differences in univariate analysis. 
A multiple regression analysis will be performed using the Cox proportional hazards 
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model to evaluate the independent effect of variables that show a significant influence on 
survival rates in the univariate analysis. 
 
Ethics 
Ethics approval was obtained on 06/07/01 (Protocol number MO60632). Data will be 
entered from January 1997 to date. Ethical clearance for data collected and analysed 
between 1997 and 2000 was obtained on 05/05/30 (Protocol number M050523). This 
research project will incorporate this existing database. 
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Appendix E 
Data Collection Sheet 
 
Sheet 1 (to be kept confidential) 
1. Hospital number 
2. Patient name and surname 
3. Study number (combination of the hospital number & patient initials)  
 
Sheet 2 (for data collection and analysis) 
1. Study number (that can be linked to patient on Sheet 1 if necessary) 
2. Demographic data namely:  
a. Date of birth 
b. Gender 
c. Ethnic group 
3. Date of presentation / diagnosis 
4. T or B-cell ALL and B-cell subtypes (Null, Common, Mature B) 
5. Treatment protocol  
6. Survival data to determine event free survival 
a. Date of remission according to bone marrow morphology 
b. Date of relapse 
c. Date last examined (assesses cases lost to follow up) 
d. Date and cause of death (namely, disease related or non-disease related 
e.g. sepsis, haemorrhage, chemotherapy related etc.) 
7. PCR (for IgH and TCR gene rearrangements) results at diagnosis & during 
treatment (including the date of each examination) 
8. Flow cytometry ( to assess percentage  of clonally restricted CD19/CD10 cells, 
cell size and DNA index) results at diagnosis & during treatment (including the 
date of each examination) 
9. Cytogenetic and FISH findings at presentation if applicable 
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